Trusted Resource for Clinical Trials, Protocols & Progress
Timelines for IND vs NDA Clinical Development in China Comparing IND and NDA Timelines in China’s Clinical Development Framework Introduction The timelines for Investigational New Drug (IND) and New Drug Application (NDA) submissions define the pace of drug development and market entry. In China, these timelines have been reshaped by sweeping reforms under the National…
Read More “Timelines for IND vs NDA Clinical Development in China” »
NMPA Regulatory Framework for Multinational Clinical Trials Understanding the NMPA’s Role in Multinational Clinical Trials in China Introduction Multinational clinical trials (MRCTs) have become the cornerstone of global drug development, ensuring that diverse patient populations are represented and regulatory requirements across regions are harmonized. China, with its rapidly expanding pharmaceutical market and significant patient pool,…
Read More “NMPA Regulatory Framework for Multinational Clinical Trials” »
